INNATE PHARMA ((GB:0EVI)), Innate Pharma SA Sponsored ADR ((IPHA)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Innate Pharma has launched a Phase 1 clinical study titled ‘A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, and preliminary efficacy of IPH4502 in patients with advanced solid tumors expressing Nectin-4, a significant step in cancer treatment research.
The intervention being tested is IPH4502, a drug designed to treat advanced solid tumors. The study involves a dose escalation phase followed by dose optimization to determine the recommended Phase 2 dose.
This interventional study uses a single-group assignment with no masking, focusing primarily on treatment. The study’s open-label design allows researchers to observe the effects of IPH4502 directly.
The study began on January 24, 2025, with the latest update submitted on July 22, 2025. These dates are crucial for tracking the study’s progress and any emerging results.
The update on this study could positively impact Innate Pharma’s stock performance by boosting investor confidence in the company’s innovative cancer treatments. This development places Innate Pharma in a competitive position within the oncology sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.